All Endocrine Disruptors General Symposia Mood and Depression Erectile Dysfunction Business PRP Testosterone Thyroid Hormones 1 Hour Courses

Testosterone for Women: The Evidence that the Guidelines Ignore (Part 5)

Free
During this webinar, Dr. Rouzier will be reviewing additional literature that describes how serum levels do not predict symptom improvement in women.  He will review the different variables affecting the action of testosterone in women which are a result of intercellular metabolism and the sensitivity of the androgen receptor. In this webinar, he will describe

Journal Club October 2022

Free
Association between pharmaceutical modulation and oestrogen in postmenopausal women in Sweden and death due to COVID-19: a cohort study Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis Twenty Years and Counting: Tamoxifen Benefits in Breast Cancer USPSTF Advises against hormone therapy to prevent chronic conditions Excess

Testosterone for Women: Current AACE Guidelines vs What the Literature Says (Part 4)

Free
During this webinar, Dr. Rouzier will review the current Endocrine Society Guidelines on the use of testosterone in women (which is against testosterone use for healthy women) unless they have Hypoactive Sexual Desire Disorder (HSDD).  This diagnosis is obtained from clinical data only and does not involve any laboratory testing.  Dr. Rouzier will describe the

Testosterone for Women: The Evidence and Benefits No One Talks About (Part 3)

Free
During this course, Dr. Rouzier reviews the current endocrine society guidelines on the use of testosterone in women (which is separate from JAMA guidelines).  As would be expected, their recommendation is to treat only if the woman has a definitive diagnosis of HSDD.  The discussion centers on the lack of reliable blood tests or levels

Testosterone for Women: The Evidence and Benefits No One Talks About (Part 2)

Free
Are you a Bronze, Silver, or Gold Member? This course is included in your membership. Take Course Now > Dr. Rouzier reviews the levels necessary to achieve symptom improvement, the levels that were measured when symptoms return, and the time frame from symptom resolution and the subsequent return of symptoms. Dr. Rouzier shares two papers that

Testosterone for Women (Part I): The Evidence and Benefits No One Talks About

Free
Are you a Bronze, Silver, or Gold Member? This course is included in your membership. Take Course Now > This series, Testosterone for Women, is an attempt to rebut a recent consensus paper and to include all the studies and data demonstrating the benefits of testosterone in women that were ignored by the authors in

Treating T3 Deficiency, The Evidence You Need – Part 10

Free
Dr. Rouzier completes the 10 Part series on Thyroid. He will be reviews a British article that describes the past 100 year of data that supports the benefits of T3 therapy over T4 alone. In addition to, the bias that surrounds thyroid treatment and why this information is suppressed when in fact patients feel better

Treating T3 Deficiency, The Evidence You Need – Part 9

Free
This course is a continuation of the same theme proving high dose replacement T3 does not cause harm nor appears to be a cardiovascular risk.  In this course, we will review the successful use of thyroid hormone in high doses.  Dr. Rouzier does not advocate doing this, whereas the purpose is to provide credence and

Treating T3 Deficiency, The Evidence You Need – Part 8

Free
During this month’s webinar, Dr. Rouzier discusses how T3 is beneficial and how high dose T3 is more preferred by patients.  We review the literature that demonstrates no harm in high dose replacement of thyroid hormone.  There is a tremendous amount of literature that supports giving high dose T3 and no problems with sudden cardiac

Treating T3 Deficiency, The Evidence You Need – Part 7

Free
Dr. Rouzier discusses the importance of utilizing research that proves harm of thyroid hormone and TSH suppression, needs to come from an outcome study (RCT of Grade A evidence) not baseline observational studies (in Graves' Disease) that prove nothing.  In addition, Dr. Rouzier reviews the epidemiology studies that show harm in hyperthyroidism from Graves Disease